Compare moats
Up to three covered companies, band by band. Every call is a curated editorial judgment, never a disclosed figure — and every band carries its cited basis.
| Advantest | Visa | Moderna | |
|---|---|---|---|
| Moat rating | wide A disclosed share that rose while margin expanded. The FY2025 Annual Securities Report and Business Report (84th term, filed 2026-06-26) lists as FY2025 progress: 'Further expanded our market share in the semiconductor tester (ATE) market (CY2024: 58%; CY2025: 65%)', earned on net sales of ¥1,128,610 million at an operating income to net sales ratio of 44.2%, 'an increase of 14.9 percentage points from the previous fiscal year'. The share is a company metric and the filing says so — 'the ratio of Advantest's semiconductor tester sales to the overall size of the semiconductor tester market', where 'The semiconductor tester market size is estimated independently by Advantest based on certain assumptions and available information'. The same filing names seven principal tester competitors (Teradyne, Inc., CCTech, Accotest, YC Corp., Cohu, Inc., UniTest Co., Ltd. and EXICON Ltd.), so this is a lead held against a named field rather than an empty one. | wide The FY2025 10-K prints a network comparison for calendar year 2024: Visa at $13,433B payments volume, 311B total transactions and 4,805M cards, against Mastercard's $8,014B / 204B / 3,146M and American Express's $1,750B / 12B / 147M. Footnote (1) sources the American Express, Diners Club / Discover, JCB and Mastercard data to The Nilson Report issue 1288 (June 2025); Visa's own line is Visa's own data. On that table Visa's payments volume is roughly two-thirds larger than the next network's, and the same section states 'Based on available data, Visa is one of the largest retail electronic funds transfer networks used throughout the world.' The rating is wide because the lead rests on a two-sided installed base the filing quantifies — nearly 5 billion payment credentials and more than 175 million merchant locations across more than 200 countries and territories — which an entrant would have to reassemble on both sides at once. The table is a single-year snapshot with no prior-year column, so it evidences the size of the lead, not its direction. | narrow The FY2025 10-K supports a real but bounded advantage. The Competition section says the company believes "mRNA as a medicine coupled with our capabilities across mRNA technology, drug discovery, development and manufacturing provide us with a competitive advantage," and the Intellectual Property section backs that with more than 260 issued or allowed U.S. patents or applications, more than 140 granted or allowed outside the U.S., 485 pending applications, and latest-to-expire granted patents on all three approved products projected to 2041 in the U.S. and 2036 in Europe. Item 1A cuts the band down from wide: it opens the competition risk with "The vaccine market, and pharmaceutical market more generally, is intensely competitive," says Moderna "ha[s] been excluded from selling our COVID vaccines in many European markets due to a competitor's contract with the European Commission, which does not lapse until year-end 2026," that in RSV it "entered a market already occupied by two larger competitors," and that rivals "have exploited and may in the future exploit their greater size, infrastructure, resources and experience." The same section reports net losses of $2.8 billion in 2025 and $3.6 billion in 2024 against 2025 total revenue of $1.9 billion. |
| Moat type | intangibles ip What management itself names as the source of the position is a proprietary platform. The July 29, 2026 Q1 FY2026 results briefing states: 'Our leading SoC Test platform, V93000, has been widely adopted across a broad range of customers in the increasingly complex AI semiconductor markets, where advanced packaging technologies including GPUs, ASICs, and CPUs are being adopted. It serves as a key foundation that underpins our competitive advantage.' The 84th-term report shows the spend behind it: R&D was approximately ¥71.4 billion in FY2024 and ¥78.1 billion in FY2025, 'The number of employees in its research and development division is approximately 30% of the Advantest workforce', and in the Test System Business Segment 'a large and ongoing investment in research and development is necessary in order to maintain market competitiveness'. Its stated IP mitigation is that 'Advantest strategically and proactively files patent applications during product development and prior to product shipment'. | network effects Visa itself names the two sides as the source of advantage: 'We believe our fundamental value proposition of security, convenience, speed and reliability as well as the number of payment credentials and our acceptance footprint help us to succeed.' In fiscal 2025 the 10-K counts nearly 5 billion payment credentials, which it defines as issued Visa card accounts, available at more than 175 million merchant locations, with nearly 14,500 financial institutions among the clients that build payment programs on Visa products. The two bases are joined through VisaNet in what the filing calls the 'four-party' model. Neither side is worth joining without the other, so the advantage is the mutual pull of the two installed bases rather than a patent estate or a cost curve. | intangibles ip The filing locates the advantage in a patent and know-how estate, not in customer lock-in or cost. Intellectual Property describes "an expansive, multi-layered IP estate" whose platform claims cover mRNA chemistry, sequence optimization, engineering elements, LNP delivery systems and "innovative processes for the manufacture and analysis of mRNA drug substance and formulated drug product," alongside "substantial proprietary know-how associated with related manufacturing processes" and a trademark portfolio of at least 1,400 registrations. Nothing in the filing claims switching costs or a cost advantage; Item 1A says the opposite, that competitors leverage "larger supply chains and greater purchasing power." |
| Leadership | clear leader The 84th-term report discloses Advantest's tester-market share at 65% in CY2025, up from 58% in CY2024, and carries the same 65% among its disclosed management metrics against a target of '58% or more'; the filing defines it as Advantest's semiconductor tester sales over a market size 'estimated independently by Advantest based on certain assumptions and available information'. The July 29, 2026 briefing names the platform behind that share — V93000, 'widely adopted across a broad range of customers in the increasingly complex AI semiconductor markets'. Teradyne, Inc. heads the filing's list of principal tester competitors. | clear leader On the 10-K's CY2024 comparison table, Visa carried 311 billion total transactions and $13,433B of payments volume against 204 billion and $8,014B for Mastercard, the largest competitor listed. American Express is next at $1,750B and 147M cards — under a seventh of Visa's payments volume and under a thirtieth of its cards — with Diners Club / Discover ($253B, 72M cards) and JCB ($319B, 167M cards) smaller still on volume. Visa's line is its own data; the competitor lines are sourced to The Nilson Report issue 1288 (June 2025) per footnote (1). | co leader The Business section opens with the company's own claim that "Moderna is a pioneer and leader in the field of mRNA medicine." The Competition section frames the commercial reality more narrowly as a contest against a small named set: "We largely compete against Pfizer and BioNTech for sales of our COVID vaccines, whose vaccine is also based on mRNA technology. We also compete against other vaccines, including Sanofi and Novavax's." It does not claim a rank anywhere, and it places Moderna behind in the other approved category: in RSV "we compete against Pfizer and GlaxoSmithKline, who entered the U.S. market prior to us, and our RSV sales have been minimal to date." |
| Pricing power | strong Q1 FY2026 gross profit was ¥255,553 million on net sales of ¥367,473 million, and the July 29, 2026 briefing states the resulting figure itself: 'Gross margin reached 69.5%', with 'an operating margin of 51.7%'. Management attributes that level to 'a favorable sales mix and limited inventory valuation losses amid the robust demand environment', not to price, and guides FY2026 full-year gross margin to 66–67% and operating margin to 49.4% after incorporating 'the impact of higher component costs, particularly for memory-related components'. FY2025 closed at a 44.2% operating margin, up 14.9 points year on year, on sales up 44.7%. | strong Visa's own take is insulated from the fees regulators target: it sets default interchange rates but does not collect them — the 10-K says 'Generally, IRFs are paid by acquirers to issuers' and that 'the fees we receive from issuers and acquirers are not derived from IRFs or MDRs.' The reported margin is high but moved down in fiscal 2025: operating income of $23,994M on $40,000M of net revenue is a 60.0% operating margin, against 65.7% ($23,595M on $35,926M) in fiscal 2024. The cause is printed two lines above operating income in the same statement — the litigation provision rose from $462M to $2,562M — and the filing says litigation provisions 'do not correlate to the underlying performance of our business' and that it excludes them 'to facilitate a comparison to our past operating performance.' Adding that provision back to operating income in both years leaves 66.4% against 67.0%, so the pricing base held and the decline is a legal charge, not a fee concession. The real limits are indirect: Dodd-Frank and the EU IFR cap interchange Visa never earns, client incentives are paid back to clients and rise with payments volume, and the UK Payment Systems Regulator holds 'wide-ranging powers and authority to review our business practices, systems, rules and fees with respect to promoting competition and innovation in the UK, and ensuring payment systems take care of, and promote, the interests of service users.' | weak Item 1A states that "certain U.S. private vaccine market practices, including regarding discounts, rebates and returns, may cause us to realize significantly lower revenues than list prices," and that "in some instances, our competitors have been able to offer more attractive terms than we can, and they may continue to do so in the future." On the flu candidate it says that in a well-developed market Moderna "may need to offer more favorable terms to gain market share (which we may be unable to do), which may negatively impact our profitability." The Commercial section adds that its markets are "characterized, particularly in the U.S. (our largest market), by a fragmented end customer base, unpredictability in orders and seasonality of deliveries." |
| Summary | Advantest sells the test step that certifies silicon before it ships, and its position there is disclosed rather than inferred: its own tester-market-share metric moved from 58% in CY2024 to 65% in CY2025 (84th-term Annual Securities Report), against a market size the filing says Advantest estimates itself. The lead is concentrated in SoC test — the July 29, 2026 briefing calls V93000 'our leading SoC Test platform' and 'a key foundation that underpins our competitive advantage' — and the customer base runs straight into the AI chain: NVIDIA International, Inc. was ¥228,273 million, or 20.2%, of FY2025 consolidated net sales, having been below the filing's 10% disclosure threshold the prior year, with Taiwan Semiconductor Manufacturing Co., Ltd. at ¥124,922 million, or 11.1%. Economics moved with it: FY2025 operating margin was 44.2%, up 14.9 points, and Q1 FY2026 gross margin reached 69.5%, which management attributes to 'a favorable sales mix and limited inventory valuation losses amid the robust demand environment' rather than to price. The counterweights sit in the same documents. The 84th-term report's customer-trust risk factor warns that if Advantest fails to meet expectations on ramp-up and post-sales service, 'the maintenance or expansion of Advantest's market share may be constrained'; it names separate competitor sets in test handlers (Hon. Precision, CCTech, Cohu, TechWing) and device interfaces (TSE, ISC, BeLINK) where no share is disclosed at all; and the July 29, 2026 briefing guides FY2026 full-year gross margin down to 66–67% having 'incorporated the impact of higher component costs, particularly for memory-related components, mainly in the second half of the fiscal year'. | Visa runs the switchboard, not the bank. The FY2025 10-K is explicit that 'Visa is not a financial institution. We do not issue cards, extend credit or set rates and fees for account holders of Visa products nor do we earn revenue from or bear credit risk with respect to any of these activities.' That disclaimer is scoped to issuing and credit extension, not to risk at large — the same filing says indemnifying issuers and acquirers for one another's settlement failures 'creates settlement risk for us' because of the timing gap between a payment transaction and its settlement. What Visa earns is service, data-processing and international-transaction revenue, reduced by client incentives, for moving other people's money: 329 billion payments and cash transactions carried the Visa brand in fiscal 2025, 258 billion of them processed by Visa, an average of 901 million a day across more than 200 countries and territories on $17 trillion of total payments and cash volume. The pull between nearly 5 billion credentials and more than 175 million merchant locations is what a rival would have to buy on both sides at once. The filing is candid about what is arriving anyway: real-time payment networks have launched in at least 80 countries behind 'strong government sponsorship and regulatory initiatives' the filing names as FedNow, PIX and UPI; B2B blockchain payments including stablecoins 'can operate globally 24/7' for cross-border transactions; and Dodd-Frank and the EU IFR both cap interchange and limit network exclusivity and routing restrictions. | Moderna's 10-K rests its competitive case on the mRNA platform and the IP wrapped around it: the company states it believes its capabilities "across mRNA technology, drug discovery, development and manufacturing" differentiate it, and reports more than 260 issued or allowed U.S. patents or applications, more than 140 granted or allowed abroad, 485 pending applications, and granted patents on Spikevax, mNEXSPIKE and mRESVIA projected to expire in 2041 (U.S.) and 2036 (Europe), plus trade secrets and manufacturing know-how it calls substantial. The filing is equally direct about the limits: the principal COVID rival's vaccine "is also based on mRNA technology"; a competitor's European Commission contract keeps Moderna out of many European COVID markets until year-end 2026; RSV sales are "minimal to date" behind Pfizer and GSK; and the risk factors warn that "the mRNA medicines field is growing rapidly, with increased competitive pressure from large and more established pharmaceutical companies." What is durable is science and plant rather than commercial position: Moderna bought and operates the Norwood (MTC) campus, completed a Marlborough site purpose-built for intismeran autogene that began shipping patient batches in September 2025, and runs UK, Canada and Australia facilities that were fully licensed in 2025, each government having entered a multi-year commitment to purchase mRNA products from the company. |
| Chain position | Back-end capital equipment: Advantest's testers certify devices after fabrication, and the 84th-term report's FY2025 major-customer table puts NVIDIA International, Inc. at 20.2% and Taiwan Semiconductor Manufacturing Co., Ltd. at 11.1% of consolidated net sales, with overseas sales 97.8% of the total. | Both a buyer and a seller of AI inside payments, not an AI infrastructure supplier: the 10-K claims 'early adoption and integration of artificial intelligence (AI) models in payment systems', sells 'risk detection and prevention solutions underpinned by real-time AI-driven scores' to issuers and acquirers, and opens its rails to third-party AI systems 'via on-demand APIs, our MCP server that enables AI systems to interface with our Visa Intelligent Commerce APIs, and fully managed solutions.' | A vertically integrated mRNA developer-manufacturer that sits between upstream licensors and government or retail buyers: it in-licenses the Penn modified-mRNA patents non-exclusively through Cellscript and mRNA RiboTherapeutics at low-single-digit royalties and NIAID's prefusion coronavirus spike and prefusion RSV F patents, manufactures drug substance at the owned Norwood MTC campus and individualized therapy at Marlborough, runs Moderna-built plants in the UK, Canada and Australia against multi-year government purchase commitments, and relies on CMOs for critical raw material production and fill-finish. |
| Products (share / barrier) |
|
|
|
| Long-horizon vote | +0.42 at weight 0.20 · swarm neutral Editorial prior, not backtested. | +0.42 at weight 0.20 · swarm neutral Editorial prior, not backtested. | +0.05 at weight 0.20 · swarm bearish Editorial prior, not backtested. |